79069-52-6

Upstream product

• 84890-97-1 (S)-3-tert-Butoxycarbonylamino-4-isobutoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 79069-16-2 benzyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoate 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 149751-93-9 N^α-(tert-butoxycarbonyl)-L-aspartic acid 4-benzyl ester N-methoxy-N-methylamide 

Downstream Products

• 331843-16-4 (S)-3-Amino-4-(4-hydroxy-phenylamino)-butyric acid benzyl ester 
• 497831-00-2 (E)-(S)-4-tert-Butoxycarbonylamino-hex-2-enedioic acid 6-benzyl ester 1-ethyl ester 
• 1236324-40-5 (3S)-4-[2-(6-benzyloxycarbonylaminohexyl)-2-tert-butoxycarbonylhydrazino]-3-tert-butoxycarbonylaminobutyric acid benzyl ester 
• 540496-34-2 (S)-(2-oxo)oxazolidine-4-acetic acid benzyl ester 
• 79069-16-2 benzyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoate 
• 911634-78-1 (S)-3-tert-butoxycarbonylamino-4-(2-hydroxy-ethylamino)-butyric acid benzyl ester 
• 497830-75-8 (3S,3aR,4S,7aR)-2-benzyl-3-benzyloxycarbonylmethyl-1-oxo-6-phenyl-1,2,3,3a,4,7a-hexahydro-pyrano[3,4-c]pyrrole-4-carboxylic acid ethyl ester 
• 497830-84-9 (E)-(S)-4-[Benzyl-((E)-4-oxo-4-phenyl-but-2-enoyl)-amino]-hex-2-enedioic acid 6-benzyl ester 1-ethyl ester 
• 497830-74-7 (3S,3aR,4S,7aR)-2-benzyl-3-benzyloxycarbonylmethyl-6-methyl-1-oxo-1,2,3,3a,4,7a-hexahydro-pyrano[3,4-c]pyrrole-4-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP

The present invention relates to compounds of azapeptide or azapeptidomimetic type of formula (I): in which R1, R2, R3, X1, X2, X3, X4 and Y are as defined in claim 1, to pharmaceutical compositions containing them and to such compounds as adjuvant for an anticancer or anti-infectious medicament.

DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT

The present invention relates to novel compounds exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV(DPP-IV), methods of preparing the same and pharmaceutical compositions containing the same as an active agent.

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl

A systematic study of anilines led to the discovery of a metabolically robust fluoroindoline replacement for the alkoxy aniline toxicophore in 1. Investigations of the P1 pocket resulted in the discovery of a wide tolerance of functionality leading to the discovery of 11 as a potent and selective inhibitor of cathepsin S.

Synthesis of densely functionalized pyrrolidinone templates by an intramolecular oxo-Diels-Alder reaction

Preparation of densely functionalized pyrrolidinone templates, is a challenge for synthetic chemists. These templates are important building blocks for novel conformationally constrained natural products or for library generation of highly functionalized

N-nitrosoanilines: A new class of caspase-3 inhibitors

Caspases are a family of cysteine proteases activated during apoptosis. In cultured human endothelial cells, physiological levels of NO prevent apoptosis and interfere with the activation of the caspase cascade. Previous studies have demonstrated that NO

Design of a potent combined pseudopeptide endothelin-a/endothelin-b receptor antagonist, ac-dBhg16-Leu-Asp-IIe-[NMe]IIe-Trp21 (PD 156252): Examination of its pharmacokinetic and spectral properties

The endothelins (ETs) are a family of bicyclic 21-amino acid peptides that are potent and prolonged vasoconstrictors. It has been shown that highly potent combined ET(A)/ET(B) receptor antagonists can be developed from the C- terminal hexapeptide of ET (H